RSS Feeds
Treatment of Chronic Immune Thrombocytopenic Purpura
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
McMillan [1] thoroughly reviewed therapeutic alternatives for patients with refractory chronic immune thrombocytopenic purpura. Another clinical concept, based on animal models and circumstantial clinical evidence, is emerging. Increasing safety and cost-effectiveness of hematopoietic stem-cell transplantation in the area of malignant diseases extended the availability of such procedures to patients with severe autoimmune disorders, including immune thrombocytopenic purpura [2, 3]. Remissions in patients with this latter condition in whom multiple therapies had previously failed and who were treated with autologous or allogeneic stem-cell transplantation have already been reported [4, 5]. The hope is that more intensive immuno-suppression, in combination with the reconstitution of a new immune system, may provide long-lasting therapeutic benefit. This approach is currently being tested clinically.
Z. Steven Pavletic, MD
University of Nebraska Medical Center; Omaha, NE 68198-3330
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
- Copyright ©2004 by the American College of Physicians
